Diagnostic value of miR-155 for acute lung injury/acute respiratory distress syndrome in patients with sepsis

Wang, Zhou-Feng; Yang, Yumin; Fan, Heng

doi:10.1177/0300060520943070

Cited by 12 publications

(5 citation statements)

References 20 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a cohort of 156 sepsis patients of whom 41 with ALI and 32 with ARDS, miR-155 levels are higher in patients with ALI or ARDS, positively correlate with IL-1b and TNF, and negatively correlate with PaO2/FiO 2 ratio. miR-155 AUC for diagnosing sepsis with ALI/ARDS is 0.87 (253). A study comparing 218 critically ill patients (135 with sepsis) with 76 healthy controls shows that, in critically ill patients ≤ 65 years, high miR-155 levels are associated with increased survival.…”

Section: Biomarker Valuementioning

confidence: 99%

Modes of action and diagnostic value of miRNAs in sepsis

Antonakos

Gilbert²,

Théroude³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Sepsis is a clinical syndrome defined as a dysregulated host response to infection resulting in life-threatening organ dysfunction. Sepsis is a major public health concern associated with one in five deaths worldwide. Sepsis is characterized by unbalanced inflammation and profound and sustained immunosuppression, increasing patient susceptibility to secondary infections and mortality. microRNAs (miRNAs) play a central role in the control of many biological processes, and deregulation of their expression has been linked to the development of oncological, cardiovascular, neurodegenerative and metabolic diseases. In this review, we discuss the role of miRNAs in sepsis pathophysiology. Overall, miRNAs are seen as promising biomarkers, and it has been proposed to develop miRNA-based therapies for sepsis. Yet, the picture is not so straightforward because of the versatile and dynamic features of miRNAs. Clearly, more research is needed to clarify the expression and role of miRNAs in sepsis, and to promote the use of miRNAs for sepsis management.

show abstract

Section: Biomarker Valuementioning

confidence: 99%

Modes of action and diagnostic value of miRNAs in sepsis

Antonakos

Gilbert²,

Théroude³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The current baseline clinical information demonstrated that patients with ARDS had a longer duration of bypass than those without ARDS, revealing its potential association with the occurrence of ARDS. Existing studies indicate that using biomarkers can improve the early diagnosis and treatment of ARDS [ 27 ]. It can delay or even prevent the progression of high-risk patients to ARDS, which is the key to reducing the incidence and mortality of ARDS, and improving its diagnosis and treatment level [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Value and Mechanism of Long Non-Coding RNA UCA1 in Acute Respiratory Distress Syndrome Induced by Cardiopulmonary Bypass

Chen¹,

Xue²,

Fang³

et al. 2023

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…A great deal of research has been done on the alternation of miRNAs in sepsis and their clinical significance. For instance, increased miR-155 levels are found in sepsis patients with acute lung injury relative to sepsis patients, and a high possibility of miR-155 predicting patients with sepsis and acute lung injury is also identified [ 24 ]. Besides, miR-328 is highly expressed in sepsis patients and rat models and it can distinguish sepsis patients from the healthy population [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-381-3p signatures as a diagnostic marker in patients with sepsis and modulates sepsis-steered cardiac damage and inflammation by binding HMGB1

Liu

Yang

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Immune response imbalance and cardiac dysfunction caused by sepsis are the main reasons for death in sepsis. This study aimed to confirm the expression and diagnostic possibility of microRNA-381-3p (miR-381-3p) and its mechanism in sepsis. Quantitative real-time PCR (qRT-PCR) and receiver operating characteristic (ROC) were used to reveal the levels and clinical significance of miR-381-3p. Pearson correlation was conducted to provide the correlations between miR-381-3p and several indexes of sepsis. The H9c2 cell models were constructed by lipopolysaccharide (LPS), and cecal ligation and puncture (CLP) was applied to establish the Sprague-Dawley (SD) rat models. Cell Counting Kit-8 (CCK-8) and flow cytometry were the methods to detect the cell viability and death rate of H9c2. Enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the concentration of inflammatory cytokines. The target gene of miR-381-3p was validated via the luciferase report system. The low expression of miR-381-3p was found in the serum of patients with sepsis. The lessened miR-381-3p could be a marker in the discrimination of sepsis patients. Overexpression of miR-381-3p could repress the mRNA expression of HMGB1, inhibit the cell apoptosis and inflammatory response, and motivate the viability of sepsis cells. At the same time, enhanced miR-381-3p promoted the inhibition of inflammation and cardiac dysfunction in the rat model of sepsis. Collectively, reduced levels of serum miR-381-3p can be used as an index to detect sepsis patients. MiR-381-3p restored the inflammatory response and myocardial dysfunction caused by sepsis via HMGB1.

show abstract

Diagnostic value of miR-155 for acute lung injury/acute respiratory distress syndrome in patients with sepsis

Cited by 12 publications

References 20 publications

Modes of action and diagnostic value of miRNAs in sepsis

Modes of action and diagnostic value of miRNAs in sepsis

Clinical Value and Mechanism of Long Non-Coding RNA UCA1 in Acute Respiratory Distress Syndrome Induced by Cardiopulmonary Bypass

MicroRNA-381-3p signatures as a diagnostic marker in patients with sepsis and modulates sepsis-steered cardiac damage and inflammation by binding HMGB1

Contact Info

Product

Resources

About